Sarepta Therapeutics (SRPT) Capital Expenditures (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Capital Expenditures of $2.1 million for Q1 2026, down 95.23% year-over-year from $43.7 million in Q1 2025, and down 42.05% quarter-over-quarter from $3.6 million in Q4 2025.
Sarepta Therapeutics (SRPT) Capital Expenditures (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $2.1 million for Q1 2026.
- In Q1 2026, Capital Expenditures fell 95.23% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $60.4 million (down 59.23% YoY), while the FY2025 annual figure was $102.0 million, down 25.54% from the prior year.
- Capital Expenditures for Q1 2026 stood at $2.1 million, down from $3.6 million in the prior quarter.
- The five-year high for Capital Expenditures was $43.7 million in Q1 2025, with the low at $2.1 million in Q1 2026.
- The 5-year median for Capital Expenditures is $19.0 million (2023), against an average of $20.5 million.
- The sharpest annual moves came in 2022 and 2026: Capital Expenditures surged 261.02% in 2022, then slumped 95.23% in 2026.
- Sarepta Therapeutics' Capital Expenditures stood at $8.0 million in 2022, then soared by 139.06% to $19.0 million in 2023, then soared by 100.02% to $38.1 million in 2024, then tumbled by 90.57% to $3.6 million in 2025, then slumped by 42.05% to $2.1 million in 2026.
- Business Quant data shows SRPT's Capital Expenditures at $2.1 million in Q1 2026, $3.6 million in Q4 2025, and $22.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 555,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 555,000.00 |
| Jun 30, 2026 | 555,000.00 |
| Mar 31, 2026 | 2.08 Mn |
| Mar 31, 2026 | 2.08 Mn |
| Dec 31, 2025 | 3.59 Mn |
| Dec 31, 2025 | 3.59 Mn |
| Sep 30, 2025 | 22.93 Mn |
| Sep 30, 2025 | 22.93 Mn |
| Jun 30, 2025 | 31.80 Mn |
| Jun 30, 2025 | 31.80 Mn |
| Mar 31, 2025 | 43.65 Mn |
| Mar 31, 2025 | 43.65 Mn |
| Dec 31, 2024 | 38.08 Mn |
| Dec 31, 2024 | 38.08 Mn |
| Sep 30, 2024 | 37.26 Mn |
| Sep 30, 2024 | 37.26 Mn |
| Jun 30, 2024 | 29.17 Mn |
| Jun 30, 2024 | 29.17 Mn |
| Mar 31, 2024 | 32.44 Mn |
| Mar 31, 2024 | 32.44 Mn |